Myelodysplastic syndrome associated with chronic valproic acid therapy: a case report and review of the literature.

Abstract

This report is of a case of myelodysplastic syndrome occurring in a 63 year old female on long-term valproic acid therapy for seizure disorder. Valproic acid therapy is widely prescribed for seizure disorders and is often associated with thrombocytopenia, macrocytic anemia and a reversible dysmyelopoiesis. There are rare reports in the literature of acute myeloid leukemia arising in patients treated with valproic acid. This case represents the first case report of a cytogenetically confirmed myelodysplastic syndrome occurring in a patient on long term valproic acid therapy and further supports that valproic acid, a histone deacetylase inhibitor, may be leukemogenic.

• Authors: Robert W Allan
• Journal: Hematology (Amsterdam, Netherlands) (Hematology) Vol. 12 Issue 6 Pg. 493-6 (Dec 2007) ISSN: 1607-8454 [Electronic] England
• PMID: 17852444 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Histone Deacetylase Inhibitors
• Valproic Acid

Topics

• Cytogenetic Analysis
• Female
• Histone Deacetylase Inhibitors
• Humans
• Middle Aged
• Myelodysplastic Syndromes (chemically induced, diagnosis)
• Seizures (complications, drug therapy)
• Valproic Acid (adverse effects)